The global cell
and gene therapy market is experiencing significant expansion, driven by
rising approvals and advancements in treatment modalities. The
market is projected to grow at a compound annual growth rate of ~23% over the
forecast period. This rapid growth is fueled by increasing
investments in biopharmaceutical R&D, favorable regulatory support, and
expanding clinical applications of gene-modified and cell-based
treatments.
Cell and gene therapy represent two transformative
approaches in modern medicine to treat or potentially cure diseases at their
root cause. Cell therapy involves the transplantation or modifying living cells
to restore or enhance their function, often used for regenerative medicine and
immunotherapy applications. Gene therapy, on the other hand, focuses on
modifying or replacing faulty genes to correct genetic disorders, cancers, and
other chronic conditions. These therapies hold immense promise for conditions
previously considered untreatable, driving extensive research and commercial
interest.
To request a free sample copy of this report, please
visit below
https://meditechinsights.com/cell-and-gene-therapy-market/request-sample/
The expanding applications of CAR-T cell therapy to drive
market growth
CAR-T (Chimeric Antigen Receptor T-cell) therapy is
revolutionizing the treatment of hematologic cancers, significantly boosting
the demand for cell and gene therapies. This therapy involves modifying a
patient’s T cells to express a receptor specific to cancer cells, allowing for
precise and potent immune responses. The dramatic success of CAR-T therapies in
treating relapsed or refractory leukemias and lymphomas have fueled their rapid
adoption. Regulatory agencies have granted approvals for multiple CAR-T
therapies, and ongoing clinical trials are expanding applications into solid
tumours and autoimmune disorders. Additionally, advancements in allogeneic
(off-the-shelf) CAR-T therapies aim to overcome existing challenges related to
patient-specific manufacturing. As CAR-T therapies' efficacy and safety
profiles improve, they are expected to play a central role in the broader
adoption of cell and gene therapies, enhancing patient outcomes and market
growth.
Next-generation gene editing technologies enhancing
precision and accessibility
Innovations in gene editing, particularly CRISPR-Cas9 and
base editing, are revolutionizing the field of gene therapy by enabling highly
precise genetic modifications. CRISPR technology allows targeted
corrections of faulty genes with minimal off-target effects, significantly
improving treatment safety and effectiveness. Furthermore, newer gene-editing
platforms, such as prime editing, offer enhanced control over genetic
alterations, expanding therapeutic possibilities for rare genetic disorders and
cancers. The integration of artificial intelligence (AI) in gene editing is
also accelerating the discovery of novel therapeutic targets and improving
editing efficiency. Additionally, advancements in non-viral delivery methods,
such as lipid nanoparticles, are making gene therapy more scalable and
accessible. As these technologies continue to evolve, they are expected to
drive a new wave of gene-based therapies, improving affordability, regulatory
acceptance, and widespread clinical adoption across diverse therapeutic areas.
Competitive
Landscape Analysis
The global cell and gene therapy market is marked by the
presence of established and emerging market players such as Sartorius
AG; Novartis AG; Thermo Fisher Scientific, Inc.; Merck KGaA; Charles River
Laboratories; Cell and Gene Therapy Catapult; Lonza; WuXi
AppTec; Takara Bio Inc.; Bristol Myers Squibb; FUJIFILM Holdings
Corporation; and F. Hoffmann-La Roche Ltd. among others. Some of
the key strategies adopted by market players include new product development,
strategic partnerships and collaborations, and geographic expansion.
🔗 Want deeper insights? Download the
sample report here:
https://meditechinsights.com/cell-and-gene-therapy-market/request-sample/
Global Cell and Gene Therapy Market Segmentation
This report by Medi-Tech Insights provides the size of
the global cell and gene therapy market at the regional- and country-level
from 2023 to 2030. The report further segments the market based on therapy
type, indication, and end-user.
Market Size & Forecast (2023-2030), By Therapy Type,
USD Million
- Cell
Therapy
- Gene
Therapy
Market Size & Forecast (2023-2030), By Indication,
USD Million
- Oncology
- Autoimmune
Diseases
- Neurological
Diseases
- Cardiovascular
Diseases
- Others
Market Size & Forecast (2023-2030), By End-user, USD
Million
- Hospitals
& Speciality Clinics
- Pharma
& Biotech Companies
- Academic
Research Institutes
- Others
Market Size & Forecast (2023-2030), By Region, USD
Million
- North
America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest
of Europe
- Asia
Pacific
- China
- India
- Japan
- Rest
of Asia Pacific
- Latin
America
- Middle
East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research
& insights firm. Our clients include Fortune 500 companies, blue-chip
investors & hyper-growth start-ups. We have completed 100+ projects in
Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research combined
with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply
side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment